The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 |
|---|---|
| Study Drug | ABBV-3067 – ABBV-2222 |
| Type of Study Drug | CFTR modulation |
| Study Title | A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation |
| Study Phase | 2 |
| Study Sponsor | Abbvie |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | 18 Years and older |